Vaccine Fails to Help CMV-Positive Stem-Cell Recipients – Managed Care magazine
FiercePharma |
Vaccine Fails to Help CMV-Positive Stem–Cell Recipients
Managed Care magazine ASP0113 (Astellas Pharma Inc./ Vical Incorporated), an investigational DNA vaccine being developed for cytomegalovirus (CMV)-seropositive hematopoietic stem cell transplant recipients, did not significantly improve overall mortality and CMV end-organ … Vical’s Astellas-partnered CMV vaccine falls short again, this time in stem cell transplant recipientsFiercePharma CMV Vaccine Falls Short in Phase III TrialOncLive |
|
News of Note—Fixing glaucoma with gene therapy, inhibiting colon cancer stem cells and building the ‘Legos of life’
FierceBiotech Although the disease can be treated with daily drops, scientists at the University of Wisconsin-Madison believe gene therapy could be a permanent cure. So they are testing a vehicle based on feline immunodeficiency virus (FIV) that’s designed to carry … |
Chemical & Engineering News |
Deals for Juno and Bioverativ put CAR–T and hemophilia in spotlight
Chemical & Engineering News Sanofi is already involved in rare diseases through its Genzyme business, which conducts R&D in Framingham, Mass. Credit: Sanofi. A photo from Sanofi Genzyme’s lab in Framingham, Mass. Sanofi is already involved in rare diseases through its Genzyme … Pharma deals, shutdown pact help stocks set more recordsLos Angeles Times Energy and technology companies lead US stocks higherCoeur d’Alene Press Stocks rise after deal to end government shutdownCBS News |
|
National Academy of Science to honor immunotherapy pioneer
Healio “Dr. Allison’s research insights and his drive to see them translated into a new therapeutic approach for patients inform our immunotherapy efforts. We are proud to have him as a leader and colleague at MD Anderson.” Allison will receive medal April 29 … |
FiercePharma |
Vaccine Fails to Help CMV-Positive Stem–Cell Recipients
P&T Community ASP0113 (Astellas Pharma Inc./ Vical Incorporated), an investigational DNA vaccine being developed for cytomegalovirus (CMV)-seropositive hematopoietic stem cell transplant recipients, did not significantly improve overall mortality and CMV end-organ … Vical’s Astellas-partnered CMV vaccine falls short again, this time in stem cell transplant recipientsFiercePharma CMV Vaccine Falls Short in Phase III TrialOncLive |